Sector News

Amgen appoints Esteban Santos EVP, Operations

June 20, 2016
Life sciences

Amgen today announced the appointment of Esteban Santos as executive vice president, Operations, effective July 25, 2016, reporting to Robert A. Bradway, chairman and chief executive officer.

Santos will be responsible for Amgen’s Operations organization which encompasses manufacturing, process development, quality, engineering and global supply chain. He will succeed Madhavan (Madhu) Balachandran, 65, who is retiring at the end of the year.

Santos, 48, has been senior vice president, Manufacturing with responsibilities for worldwide product supply since 2013. He joined Amgen in 2007 and previously held various leadership roles, including vice president, Drug Product; vice president, Site Operations; vice president, Manufacturing; and vice president, Engineering.

Before joining Amgen, Santos was site general manager for the Johnson & Johnson (J&J) Cordis operation in Puerto Rico. Prior to J&J, Santos held several management positions in General Electric’s industrial and transportation businesses in Puerto Rico, Connecticut, and Pennsylvania. Santos holds a bachelor of science degree in electrical engineering from the University of Puerto Rico – Mayagüez and a master of science in management from the Rensselaer Polytechnic Institute, Hartford, Connecticut.

Bradway said, “Esteban is a talented leader with a proven track record. I’m confident that Esteban and our Operations team will maintain our track record of industry-leading performance in serving ‘every patient, every time’ as we expand globally, launch new products and introduce our next-generation of biomanufacturing technologies.”

Succeeding Santos as senior vice president, Manufacturing will be Robert Maroney, who is currently vice president, Site Operations at Amgen Manufacturing, Ltd. in Juncos, Puerto Rico.

Source: Amgen

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).